Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CGC-11047 in Metastatic Hormone Refractory Prostate Cancer
NCT00585416Phase 2Terminated
- Sponsor
- University of Wisconsin–Madison
- Start
- Jun 2006
- Primary completion
- Nov 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of PG-11047 in prostate cancer (PCa), sponsored by University of Wisconsin–Madison. Primary endpoint: Efficacy at 8 weeks. Started Jun 2006; status: terminated.
02
Drugs
PG-11047
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00585416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00585416.